Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-huJ591 PET in Metastatic Prostate Cancer
NCT01543659Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2012
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 89Zr-DFO-huJ591 in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Ability of 89Zr-DFO-huJ591 PET to detect known sites of disease at 3 years and Pharmacokinetics (PK) and biodistribution of 89Zr-DFO-huJ591 PET at 3 years. Started Feb 2012; status: completed.
02
Drugs
89Zr-DFO-huJ591
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01543659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543659.